Physician profile
Chana Abrams
NPI 1982843157
$7,048.27
in general payments reported to CMS, 2019-2025
47 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.55 · 2021: $1,399 · 2022: $1,886 · 2023: $1,399 · 2024: $1,233 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671 · Education: $72.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.35 |
| Education | $72.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,854.22 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $852.47 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $739.43 | 2021-2025 | |
| Novo Nordisk INC | $390.66 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.20 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $268.29 | 2021-2024 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $216.61 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Esperion Therapeutics, INC. | $205.03 | 2021-2022 | |
| Genzyme Corporation | $178.57 | 2021-2024 | |
| Abbott Laboratories | $173.10 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $161.67 | 2021-2025 | Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $138.51 | 2022 | |
| Amarin Pharma, INC. | $122.56 | 2021-2022 | |
| Pfizer INC. | $115.70 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $111.93 | 2023 | Gvoke Hypopen |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $100.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $94.40 | 2021 | |
| Eisai INC. | $83.17 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.99 | 2022-2024 | Vpriv |
| Cleerly, INC. | $67.13 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Sanofi Pasteur INC. | $65.28 | 2022-2025 | |
| Glaxosmithkline, LLC. | $64.91 | 2022-2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $58.95 | 2021-2023 | |
| Horizon Therapeutics Plc | $41.21 | 2022-2023 | Krystexxa |
| Meditrina | $40.86 | 2020-2021 | |
| Exact Sciences Corporation | $37.67 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $35.93 | 2025 | Zoryve |
| Nevro Corp. | $34.94 | 2023 | Senza |
| Tactile Systems Technology INC | $31.62 | 2025 | Flexitouch Plus, Nimbl |
| Teva Pharmaceuticals USA, INC. | $31.20 | 2022 | |
| Philips North America LLC | $27.17 | 2024 | (Cm9) Amb Mon & Diag Und |
| Corcept Therapeutics | $24.25 | 2022 | |
| Medtronic, INC. | $24.17 | 2022 | |
| Axsome Therapeutics, INC. | $23.69 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $21.70 | 2023 | Gemtesa |
| Dexcom, INC. | $21.38 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $20.34 | 2024 | Flucelvax, Fluad |
| Neurocrine Biosciences, INC. | $19.62 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.75 | 2023 | Eliquis |
| Arbor Pharmaceuticals, INC. | $15.68 | 2022 | |
| Irhythm Technologies, INC. | $15.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.32 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.08 | 2025 | Nuzyra, Xhance |
| Therapeuticsmd, INC. | $14.57 | 2021 | |
| Millicent US INC | $12.84 | 2021 | |
| Avion Pharmaceuticals | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chana Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.